Gsk (GSK) Operating Expenses (2009 - 2026)

Gsk (GSK) has 18 years of Operating Expenses data on file, last reported at -$12.7 billion in Q3 2026.

• For the quarter ending Q3 2026, Operating Expenses changed N/A year-over-year to -$12.7 billion; the trailing twelve-month figure through Sep 2026 stood at -$47.6 billion (changed N/A YoY), and the FY2025 full-year result was -$22.1 billion, up 0.74% from the prior year.
• Operating Expenses was -$12.7 billion for Q3 2026 at Gsk, down from -$7.6 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$3.9 billion in Q1 2022 to a low of -$22.4 billion in Q4 2024.
• A 5-year average of -$8.6 billion and a median of -$5.1 billion in 2026 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses plunged 122.3% in 2022 and gained 22.43% in 2025, its largest moves.
• Gsk's Operating Expenses stood at -$16.3 billion in 2022, then slipped by 19.16% to -$19.4 billion in 2023, then slipped by 15.39% to -$22.4 billion in 2024, then increased by 1.14% to -$22.1 billion in 2025, then jumped by 42.41% to -$12.7 billion in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were -$12.7 billion in Q3 2026, -$7.6 billion in Q2 2026, and -$5.1 billion in Q1 2026.